Jabbour Jerome D 4
4 · Matinas BioPharma Holdings, Inc. · Filed Jun 22, 2018
Insider Transaction Report
Form 4
Jabbour Jerome D
DirectorPresident and CEO
Transactions
- Purchase
Series B Convertible Preferred Stock
2018-06-21$1000.00/sh+15$15,000→ 15 totalExercise: $0.50From: 2018-06-21→ Common Stock (30,000 underlying)
Footnotes (1)
- [F1]On June 21, 2018, the Reporting Person purchased 15 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date.